EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME. - PIMS (Plaque Imaging Molsidomine Study)
100 项与 Therabel Pharmaceuticals Ltd. 相关的临床结果
0 项与 Therabel Pharmaceuticals Ltd. 相关的专利(医药)
100 项与 Therabel Pharmaceuticals Ltd. 相关的药物交易
100 项与 Therabel Pharmaceuticals Ltd. 相关的转化医学